| Abstract [eng] |
Ovarian cancer is the 8th leading cause of cancer and cancer-related deaths in oncogynecologic malignancies. Currently used ovarian cancer biomarkers in clinical practice (HE4 and CA125) exhibits limited sensitivity and specificity, highlighting the need for identification of new diagnostic and prognostic biomarkers. The aim – to assess the diagnostic and prognostic accuracy of 27 biomarkers (gene expression, gene mutation and gene promotor methylation) chosen by literature and public database analysis. The study results demonstrated that gene expression biomarkers CTNNB1, GRB7 and TCEAL4 may have diagnostic value, and ARID1A mutations, NOTCH4 and HES1 gene expression has prognostic properties. Biomarkers combinations were associated with improved diagnostic and prognostic performance of the developed ovarian cancer models. Thus, the obtained results indicate the potential clinical relevance of the analyzed biomarkers, after futher validation these biomarkers and their combinations could contribute to more accurate diagnosis and prognosis of ovarian cancer. |
